Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Science Translational Medicine|November 27, 2015
Is all cancer therapy immunotherapy?Marcia Belvin, Ira Mellman
EMBO Reports|January 14, 2003
DmMyD88 controls dorsoventral patterning of the Drosophila embryoZakaria Kambris, Hana Bilak, Rosalba D'Alessandro, et al.
Plos One|October 7, 2016
Metabolic Response to NAD Depletion across Cell Lines Is Highly VariableYang Xiao, Mandy Kwong, Anneleen Daemen, et al.
Nature|March 26, 2002
The Drosophila immune response against Gram-negative bacteria is mediated by a peptidoglycan recognition proteinMarie Gottar, Vanessa Gobert, Tatiana Michel, et al.
Cancer Chemotherapy and Pharmacology|October 12, 2012
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenograftsEdna F Choo, Chee M Ng, Leanne Berry, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 17, 2009
Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacyHarvey Wong, Marcia Belvin, Sylvia Herter, et al.
Science (New York, N.Y.)|December 20, 2003
Dual activation of the Drosophila toll pathway by two pattern recognition receptorsVanessa Gobert, Marie Gottar, Alexey A Matskevich, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 15, 2010
Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitorEdna F Choo, Marcia Belvin, Jocelyn Chan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 12, 2010
Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941Laurent Salphati, Harvey Wong, Marcia Belvin, et al.
Science Translational Medicine|September 10, 2010
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancerJeffrey J Wallin, Jane Guan, Wei Wei Prior, et al.
Pageof 6